Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2/3 2Phase 2 2Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 13Leukemia 4Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3Congenital Abnormalities 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Biphenotypic, Acute 2Thrombocythemia, Essential 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasm, Residual 1Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Burkitt Lymphoma 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Dexamethasone 8Cytarabine 7Cyclophosphamide 7venetoclax 6Vincristine 6Methotrexate 5merphos 4Rituximab 4Prednisone 4pegaspargase 3fludarabine phosphate 3dexamethasone acetate 3dexamethasone 21-phosphate 3Peripheral Blood Stem Cell Transplantation 3Filgrastim 3Calcium Dobesilate 3ruxolitinib 2prednylidene 2nelarabine 2deltacortene 2auricularum 2Whole-Body Irradiation 2Specimen Handling 2Pentetic Acid 2Mycophenolic Acid 2Injections 2Granulocyte Colony-Stimulating Factor 2Everolimus 2Etoposide 2Decitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Daunorubicin × Clear all
NCT05320380 2023-09-01

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Children's Oncology Group

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡